Party Drug Ketamine (Special K) Likely To Become Anti-Depression Medicine
The drug Ketamine, known in the party scene as "Special K," could have a future in depression treatment. Pharmaceutical companies are racing to create a patentable version of the drug and researchers are trying to learn more about the effects it has on the brain. Ketamine works by blocking the signalling molecule NMDA, which is a component of the glutamate pathway. This pathway is involved with memory and cognition, psychiatrist James Murrough at the Mount Sinai Hospital in New York City, explained to Nature magazine.
- Dr. James Murrough, Assistant Professor, Psychiatry, Neuroscience, Icahn School of Medicine at Mount Sinai
Mount Sinai Study Reveals Genetic Clues Explaining Why Obesity Affects People Differently
Sep 15, 2025 View All Press Releases
Lung Cancer Rewires Immune Cells in the Bone Marrow to Weaken Body’s Defenses
Sep 10, 2025 View All Press Releases
Single Hair Strand Could Provide Biomarker for ALS, Mount Sinai Study Finds
Sep 04, 2025 View All Press Releases
New AI Tool Addresses Accuracy and Fairness in Data to Improve Health Algorithm
Sep 04, 2025 View All Press Releases
Mount Sinai Study Discovers Potential Link Between Stress and Type 2 Diabetes
Sep 03, 2025 View All Press Releases
